182 related articles for article (PubMed ID: 15846380)
1. Central serous chorioretinopathy associated with testosterone therapy.
Ahad MA; Chua CN; Evans NM
Eye (Lond); 2006 Apr; 20(4):503-5. PubMed ID: 15846380
[No Abstract] [Full Text] [Related]
2. The potential role of testosterone in central serous chorioretinopathy.
Grieshaber MC; Staub JJ; Flammer J
Br J Ophthalmol; 2007 Jan; 91(1):118-9. PubMed ID: 17179128
[No Abstract] [Full Text] [Related]
3. Central serous chorioretinopathy as a complication of postcardiac transplant corticosteroid therapy.
Singh AD; Demirci H; Shields CL; Shields JA
Eye (Lond); 2003 May; 17(4):522-4. PubMed ID: 12802354
[No Abstract] [Full Text] [Related]
4. An unusual case of central serous chorioretinopathy in a patient with acute retinal necrosis.
Stuebiger N; Biester S; Deuter CM; Zierhut M
Ocul Immunol Inflamm; 2008; 16(3):109-11. PubMed ID: 18569799
[TBL] [Abstract][Full Text] [Related]
5. The adverse effects of corticosteroids in central serous chorioretinopathy.
De Nijs E; Brabant P; De Laey JJ
Bull Soc Belge Ophtalmol; 2003; (289):35-41. PubMed ID: 14619628
[TBL] [Abstract][Full Text] [Related]
6. Testosterone replacement in elderly men.
Baum NH; Crespi CA
Geriatrics; 2007 Sep; 62(9):15-8. PubMed ID: 17824721
[TBL] [Abstract][Full Text] [Related]
7. Risks of testosterone replacement.
Redmond G
N Engl J Med; 2004 May; 350(19):2004-6; author reply 2004-6. PubMed ID: 15131838
[No Abstract] [Full Text] [Related]
8. Central serous chorioretinopathy in a patient taking sildenafil citrate.
Allibhai ZA; Gale JS; Sheidow TS
Ophthalmic Surg Lasers Imaging; 2004; 35(2):165-7. PubMed ID: 15088831
[TBL] [Abstract][Full Text] [Related]
9. Risks of testosterone-replacement therapy and recommendations for monitoring.
Rhoden EL; Morgentaler A
N Engl J Med; 2004 Jan; 350(5):482-92. PubMed ID: 14749457
[No Abstract] [Full Text] [Related]
10. The uses and misuses of testosterone therapy.
Johns Hopkins Med Lett Health After 50; 2006 Aug; 18(6):3, 7. PubMed ID: 16921650
[No Abstract] [Full Text] [Related]
11. Central serous chorioretinopathy in patients receiving systemic corticosteroid therapy.
Levy J; Marcus M; Belfair N; Klemperer I; Lifshitz T
Can J Ophthalmol; 2005 Apr; 40(2):217-21. PubMed ID: 16049541
[No Abstract] [Full Text] [Related]
12. Central serous chorioretinopathy associated with sildenafil.
Fraunfelder FW; Fraunfelder FT
Retina; 2008 Apr; 28(4):606-9. PubMed ID: 18398363
[TBL] [Abstract][Full Text] [Related]
13. 54-year-old man with breast cancer after prolonged testosterone therapy.
Sorscher S; Krause W
Clin Adv Hematol Oncol; 2005 Jun; 3(6):475; discussion 476. PubMed ID: 16167025
[No Abstract] [Full Text] [Related]
14. Testosterone and ageing: what have we learned since the Institute of Medicine report and what lies ahead?
Miner MM; Seftel AD
Int J Clin Pract; 2007 Apr; 61(4):622-32. PubMed ID: 17343664
[TBL] [Abstract][Full Text] [Related]
15. Testosterone replacement therapy for older men.
Wald M; Meacham RB; Ross LS; Niederberger CS
J Androl; 2006; 27(2):126-32. PubMed ID: 16474018
[No Abstract] [Full Text] [Related]
16. Prostate-specific antigen testing in hypogonadism: implications for the safety of testosterone-replacement therapy.
Gould DC; Feneley MR; Kirby RS
BJU Int; 2006 Jul; 98(1):1-4. PubMed ID: 16831134
[TBL] [Abstract][Full Text] [Related]
17. [Risks, contraindications, abuse and monitoring risks of testosterone replacement therapy (TRT)].
Glina S; Wroclawski ER; Chaves OH
Int Braz J Urol; 2006; 32 Suppl 1():31-4. PubMed ID: 23631039
[No Abstract] [Full Text] [Related]
18. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.
Coward RM; Simhan J; Carson CC
BJU Int; 2009 May; 103(9):1179-83. PubMed ID: 19154450
[TBL] [Abstract][Full Text] [Related]
19. Central serous chorioretinopathy.
Marcuson J; Riley T
Optometry; 2008 May; 79(5):241-51. PubMed ID: 18436164
[TBL] [Abstract][Full Text] [Related]
20. Testosterone replacement therapy for male hypogonadism: part III. Pharmacologic and clinical profiles, monitoring, safety issues, and potential future agents.
Seftel A
Int J Impot Res; 2007; 19(1):2-24. PubMed ID: 16193074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
